Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.05 | 1.18203309693 | 4.23 | 4.55 | 3.9 | 841335 | 4.24356915 | CS |
| 4 | -0.59 | -12.1149897331 | 4.87 | 7.38 | 3.9 | 1378412 | 5.41595135 | CS |
| 12 | -1.04 | -19.5488721805 | 5.32 | 7.38 | 3.9 | 911978 | 5.38337719 | CS |
| 26 | 1.22 | 39.8692810458 | 3.06 | 7.38 | 2.39 | 1078029 | 4.25364739 | CS |
| 52 | -14.14 | -76.7643865364 | 18.42 | 18.9 | 2.39 | 978421 | 5.20166418 | CS |
| 156 | -11.22 | -72.3870967742 | 15.5 | 20.71 | 2.13 | 785702 | 7.00727166 | CS |
| 260 | -11.22 | -72.3870967742 | 15.5 | 20.71 | 2.13 | 785702 | 7.00727166 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
